Tag: xarelto
New VOYAGER PAD analysis confirms consistent benefit of low-dose rivaroxaban plus...
Data from a new prespecified analysis of the phase III VOYAGER PAD clinical trial show that low-dose rivaroxaban plus aspirin resulted in a 33%...
Vascular News’ top 10 most popular stories of August 2021
Research presented at the Society for Vascular Surgery’s Vascular Annual Meeting (SVS VAM 2021; 18–21 August, San Diego, USA and online)—including new VOYAGER PAD...
FDA approves expanded PAD indication for Xarelto plus aspirin to include...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the US Food and Drug Administration (FDA) has approved an expanded peripheral arterial...
Janssen submits application to US FDA for new indication to expand...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the US Food and...
Positive NICE recommendation for Xarelto to prevent atherothrombotic events in CAD...
The National Institute for Health and Care Excellence (NICE) has published the final appraisal determination (FAD) recommending the use of Xarelto (rivaroxaban) by the...
Rivaroxaban recommended by NICE for peripheral and coronary artery disease patients
The National Institute for Health and Care Excellence (NICE) in the UK has published a positive draft final appraisal determination recommending the use of...
PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in...
Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at...
Rivaroxaban gets FDA approval for treatment in CAD or PAD
Rivaroxaban, brand name Xarelto (Janssen), has received approval by the US Food and Drug Administration (FDA) to reduce the risk of major cardiovascular (CV)...
Bayer announces new licensed indication for use of Xarelto in patients...
Xarelto, co-administered with aspirin, is indicated in the EU for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or...
Janssen submits application for new Xarelto (rivaroxaban) indications for CAD and...
Janssen has submitted a supplemental new drug application to the US Food and Drug Administration (FDA) for two new Xarelto (rivaroxaban) vascular indications: reducing the...
Xarelto (rivaroxaban) reduces risk of major amputation by 70% in peripheral...
Bayer and its cooperation partner Janssen Research & Development have announced two publications of further data from the Phase III COMPASS study in The...
ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...
The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...
COMPASS study of Janssen’s rivaroxaban to end early for efficacy
The phase three COMPASS trial, evaluating the efficacy and safety of rivaroxaban (Xarelto, Janssen) for the prevention of major adverse cardiac events, including cardiovascular...
Two new real-world studies confirm positive efficacy and safety profile of...
Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...
